Patents by Inventor Jeremy W. Thorner

Jeremy W. Thorner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11248216
    Abstract: The present disclosure provides genetically modified cells and non-human organisms, and methods of producing such cells and organisms. Also provided are methods of editing the genome of such cells and organisms. The cells and non-human organisms of the disclosure are genetically modified such that their genome includes an integrated heterologous nucleic acid (that includes a CRISPR/Cas target sequence) at one or more (e.g., 2 or more, 3 or more, 4 or more, etc.) positions within the genome. The integrated nucleic acids, which include the same CRISPR/Cas target sequence, allow for simultaneous gene editing at multiple different positions within a genome using a single species of CRISPR/Cas guide RNA (i.e., one guide RNA will target multiple sites because the multiple sites have the same target sequence).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Jeremy W. Thorner, Gregory Charles Finnigan
  • Publication number: 20190194632
    Abstract: The present disclosure provides genetically modified cells and non-human organisms, and methods of producing such cells and organisms. Also provided are methods of editing the genome of such cells and organisms. The cells and non-human organisms of the disclosure are genetically modified such that their genome includes an integrated heterologous nucleic acid (that includes a CRISPR/Cas target sequence) at one or more (e.g., 2 or more, 3 or more, 4 or more, etc.) positions within the genome. The integrated nucleic acids, which include the same CRISPR/Cas target sequence, allow for simultaneous gene editing at multiple different positions within a genome using a single species of CRISPR/Cas guide RNA (i.e., one guide RNA will target multiple sites because the multiple sites have the same target sequence).
    Type: Application
    Filed: April 20, 2017
    Publication date: June 27, 2019
    Inventors: Jeremy W. Thorner, Gregory Charles Finnigan
  • Patent number: 5077204
    Abstract: Methods and compositions are provided for endopeptidase production, enhanced efficiencies of processing in vivo and in vitro to provide for process polypeptides, and purified enzyme for in vitro processing of polypeptides. The endopeptidase is specific for dibasic amino acid sites, cleaving at the C-side of the dipeptide.The S. cerevisiae strain pYBCA-5 (truncated KEX2) was deposited at the A.T.C.C. on June 21, 1984 and given Accession No. 20717.
    Type: Grant
    Filed: April 8, 1988
    Date of Patent: December 31, 1991
    Assignees: Chiron Corporation, The Regents of the University of California
    Inventors: Anthony J. Brake, Lindley C. Blair, David Julius, Jeremy W. Thorner